Bleeding in acute coronary syndromes.
Granger
Christopher B
CB
Department of Medicine, Division of Cardiology, Duke University School of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
D000208:Acute Disease; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000990:Antithrombin III / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D000077425:Fondaparinux; D006470:Hemorrhage / Q000209:etiology* / Q000503:physiopathology; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D012042:Registries; D012720:Severity of Illness Index; D013577:Syndrome; D013921:Thrombocytopenia / Q000139:chemically induced / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D011134:Polysaccharides; D000990:Antithrombin III; D006493:Heparin; D000077425:Fondaparinux